

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden

hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934  
or Section 30(h) of the Investment Company Act of 1940

<b>1. Name and Address of Reporting Person*</b> <u>Abrams Michael J.</u> <hr/> (Last) (First) (Middle) C/O TEKIRA PHARMACEUTICALS CORP. SUITE 100, 8900 GLENLYON PARKWAY <hr/> (Street) BURNABY A1 V5J 5J8 <hr/> (City) (State) (Zip)	<b>2. Date of Event Requiring Statement (Month/Day/Year)</b> 01/01/2015	<b>3. Issuer Name and Ticker or Trading Symbol</b> <u>TEKIRA PHARMACEUTICALS Corp [ TKMR ]</u> <hr/> <b>4. Relationship of Reporting Person(s) to Issuer (Check all applicable)</b> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) EVP & Chief Discovery Officer	<b>5. If Amendment, Date of Original Filed (Month/Day/Year)</b>  <hr/> <b>6. Individual or Joint/Group Filing (Check Applicable Line)</b> <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
---	--	--	---

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	10,875	D	

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (Right to Buy)	12/09/2008	12/08/2018	Common Shares	5,000	1.8 <sup>(1)</sup>	D	
Employee Stock Option (Right to Buy)	01/28/2010	01/27/2020	Common Shares	5,000	3.85 <sup>(1)</sup>	D	
Employee Stock Option (Right to Buy)	08/10/2011	08/09/2021	Common Shares	5,000	2.4 <sup>(1)</sup>	D	
Employee Stock Option (Right to Buy)	12/23/2011	12/22/2021	Common Shares	5,000	1.7 <sup>(1)</sup>	D	
Employee Stock Option (Right to Buy)	12/10/2012	12/09/2022	Common Shares	5,000	5.15 <sup>(1)</sup>	D	
Employee Stock Option (Right to Buy)	01/02/2014	01/01/2024	Common Shares	75,000	8.3 <sup>(1)</sup>	D	
Employee Stock Option (Right to Buy)	03/30/2008	09/12/2015	Common Shares	17,044	0.4444 <sup>(1)(2)</sup>	D	
Employee Stock Option (Right to Buy)	03/30/2008	12/31/2015	Common Shares	5,445	0.4444 <sup>(1)(2)</sup>	D	
Employee Stock Option (Right to Buy)	03/30/2008	04/03/2017	Common Shares	675	0.4444 <sup>(1)(2)</sup>	D	
Employee Stock Option (Right to Buy)	03/30/2008	05/27/2017	Common Shares	13,503	0.4444 <sup>(1)(2)</sup>	D	
Warrants	02/29/2012	03/01/2017	Common Shares	2,500	2.6 <sup>(1)</sup>	D	

**Explanation of Responses:**

1. Expressed in Canadian dollars.

2. Represents stock options of Protivia Biotherapeutics Inc., a subsidiary of the Issuer. The options are exercisable for common shares of the Issuer.

**Remarks:**

/s/ Michael J. Abrams

12/31/2014

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.